Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
Our 225-page report provides 192 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this nascent pharmaceutical market.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis), product profiles and commercial developments. Read the full transcripts of one exclusive expert opinion interview from an industry specialist informing your understanding and allowing you to assess prospects for investments and sales, including: • Dr Katarzyna Nej-Wolosiak, Medical Science Lead, SOTIO
See revenue forecasts for the most promising products in development How will leading prostate cancer drugs and devices perform to 2025 at world level? Our study forecasts sales of 9 leading drugs, including: • Zytiga • Xtandi • Xofigo • Lupron • Zoladex • Taxotere • Provenge
Furthermore, this report will show your revenue forecast to 2025 for 5 leading procedures: • Brachytherapy • Radical prostatectomy • External beam radiation • Cryotherapy • HIFU
Discover how high revenues can go. Our analysis also breaks the main world forecast into geographical markets.
What are the prospects in the leading regions and countries? In addition to analyses of the overall world market, you discover individual revenue forecasts to 2025 for: • US • EU5 (Germany, France, Italy, Spain and the UK) • Japan • South Korea • India • China • Brazil • Russia • Mexico • Rest of the World
There will be growth in both developed and developing pharmaceutical markets. Our analyses show that the “Rest of the world” market will achieve high revenue growth by 2025.
Leading companies and potential for market growth Overall, world revenue for prostate cancer therapies will reach $8.3bn in 2015, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, an increasing patient population and diagnostic rates will result in a significant increase in sales over the next decade.
See Visiongain’s analysis of 7 leading companies, including these: • Johnson & Johnson • AstraZeneca • Varian Medical Systems • Elekta • Sanofi • AbbVie • Theragenics
A company profile gives you the following information where available: • Historical revenues • Discussion of a company’s activities and outlook, including promising pipeline products • Recent financial results • Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
Research and development – assess innovation, trends and possibilities What about R&D – the pipeline for new drugs? You see trends for these areas and technologies: • Immunotherapies • Gene therapies • Androgen Receptor Antagonists
New prostate cancer drugs are in great demand to allow patients more personalised treatment plans. Our work explains, discussing many issues.
How the Prostate Cancer Therapeutics Market Forecast 2015-2025: Opportunities for Leading Companies report helps you In summary, our 225 page report gives you the following knowledge: • Market forecasts to 2025 for the prostate cancer drugs and devices markets – find out what the next decade holds for both markets, assessing annual growth rates and market shares. • Revenue forecasts to 2025 for the leading national markets • Predicted revenues of 9 leading drugs to 2025 – see potentials of top products • Assessment of 7 leading companies – hear about products, results and strategies including pipeline analysis and recent developments • Review of R&D pipelines – investigate developmental trends and progress • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market • View interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the prostate cancer therapeutics market and leading the leading companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 The Prostate Cancer Therapeutics Market Overview
1.2 Prostate Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Cancer
2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Functioning Apoptotic Pathways
2.2.3 Lack of Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors in Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Prostate Cancer Screening: Does The Cost Justify The Means?
2.8.4 Alternative Tests Could Change Diagnostics
2.9 Treating Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010
3. The Prostate Cancer Therapeutics Market 2015-2025
3.1 The Global Prostate Cancer Therapeutics Market, 2014
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2015-2025
3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2015-2025
4. The Prostate Cancer Drugs Market 2015-2025
4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition
4.2 The Prostate Cancer Drugs Market, 2014
4.3 Leading Prostate Cancer Drugs: Market Forecast, 2015-2025
4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
